Company Profile

ExoCyte Therapeutics Pte. Ltd. (ExoCyte) is a Singapore incorporated biotechnology company with a novel cancer vaccine strategy that represents the next generation of personalized cancer immunotherapy.   We are developing the means by which to educate a patient’s immune system to fight their malignancy. ExoCyte’s vaccine strategy is premised on the electroporation of tumor-derived exosomes into autologous dendritic cells which are then co-administered with an immunostimulant that enhances the patient’s anti-cancer immune response. Read more...

Technology Platforms

ExoCyte’s patented vaccine technology directly educates a cancer patient’s own immune system by activating their dendritic cells to fight their disease.  “Dendritic cells” are the master orchestrators of the immune response that trigger the cascade of antibody production and activation of T-cells, killer cells, etc. that circulate to identify and then fight diseases. “Antigens” are the genetic and protein markers that characterize tumors. “Exosomes” are microvesicles containing tumor antigens that are released by tumors into biological fluids. Read more...

Vaccine Strategy

Tumor-derived exosomes are harvested from a patient’s peripheral blood (or other body fluid) together with the patient’s immune cells which are subsequently matured into dendritic cells.  The exosomes are inserted into the patient's dendritic cells using flow electroporation and the loaded dendritic cells are administered to the patient as a course of vaccine injections.  Back inside the body, the dendritic cells process the patient-specific cancer-derived genetic and protein information from the exosomes and drive an immune response against the tumor through both antibody and cellular attacks. Read more...